Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection

Surgeries

The trial was designed to compare effectiveness and safety of surgeries in the patients with non-small cell lung cancer

The trial is a multi-centre, real-world, non-interventional, observational study. The Chinese elderly pathologically diagnosed patients with early-stage non-small cell lung cancer enrolled from 2015 to 2017 who received lobectomy or segment/wedge dissection were included and the study data on patient demographic/tumor biological characteristics, and clinical treatments were retrospectively collected to evaluate effectiveness and safety of the surgeries.

A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Surgeries in the Chinese Early-stage Patients With Non-small Cell Lung Cancer

Overall survivals in the subgroups categorised by age, tumor size, and clinical/pathological staging

Impact factors of overall survival as measured by patient demographic/tumor biological characteristics

Death rate within 30/90 days after surgeries

LinkDoc Technology (Beijing) Co. Ltd.

China-Japan Friendship Hospital

Professor

jianxing He, President

wenhua Liang, Director

Chao Lv, Deputy Director

Zitong Wang, Director

Naixin Liang, Deputy Director

Fan Yang

Shaohua Ma, Director

Yi Zhang, Director

Zhiqiang Wang

Xiaojie Pan, Deputy Director

Jian Zhao, Director

Guibin Qiao, Director

Jianxing He, President

Jianjun Lu, Director

Lin Yang, Deputy Director

Jie Chen, Deputy Director

Lei Xian, Director

Fanyi Kong

Junfeng Liu, Director

Mingfei Geng, Director

Li Wei, Director

Yongde Liao

Chunfang Zhang, Director

Liang Chen, Director

Xiaoqiang Liu, Deputy Director

Haitao Ma, Director

Bentong Yu, Director

Dongliang Yu, Director

Wei Liu, Director

Hua Xin, Director

Changhong Liu

Suning Zhang, Director

Shun Xu, Director

Zhiyong Su, Director

Zhanlin Guo, Director

Hui Tian

Baijiang Zhang, Director

Zeshu Li, Director

Hecheng Li, Director

Xiaoqing Zhao

Songtao Xu, Deputy Director

Hongguang Zhang

Lunxu Liu, Vice President

Tianyang Dai

Xun Zhang

Jun Chen, Director

Zhengfu He

Jian Hu, Director

Ying Chai, Director

Qixun Chen, Director

Weiyu Shen, Director

Guangmao Yu

Baofu Chen

This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR Mutation-Positive in the real world. The secondary purpose was to observe the postoperative follow-up treatment pattern and its subgroups (based on different EGFR mutation status and different clinical stages).

About 2,000 eNSCLC patients who received radical resection from about 50 research centers across the country will be included in this study, and will be followed up to 2 years after enrollment according to the actual clinical situation. The analysis method of this study is mainly based on descriptive statistics. The information about the human genetic resources of the subjects to be collected includes: demography, physical examination, WHO fitness status, medical history, smoking history, disease characteristics, surgical information, initial and follow-up adjuvant treatment pattern, laboratory tests, survival status, and adverse events related to gefitinib/osimertinib, serious adverse events/non-severe ADR, measures taken for adverse events, outcome of adverse events.

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

A Prospective, National, Multi-center, Non-intervention Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

Descriptive summary statistics ( total number of cases, number of missing cases, frequency, and percentage of each category) were used to describe the distribution of participants with initial adjuvant treatment patterns, including chemical, targeted, combined, or other therapy.

Set subgroup analysis for different initial adjuvant treatment pattern, including different clinical stages (according to phase I/ Phase II/ stage III) and different EGFR mutation status (19del or 21 L858R);

Calculate the time from the start date to the end of initial adjuvant treatment. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

Calculate the interval of operation to the adjuvant therapy with EGFR-TKI, which is classified into single-drug therapy and combined therapy. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

The patients with chemotherapy were mainly calculated, divided into chemotherapy and targeted combination chemotherapy. The total number of chemotherapy cycles, the number of missing cases, the mean, standard deviation, the median, the 25th and 75th percentiles, the minimum and the maximum were statistically described

Descriptive summary statistics ( total number of cases, number of missing cases, frequency, and percentage of each category) were used to describe the distribution of participants with follow-up treatment patterns after advanced events evaluated by an investigator, including chemical, targeted, combined, or other therapy.

Set subgroup analysis for different follow-up treatment pattern including different clinical stages (according to phase I/ Phase II/ stage III) and different EGFR mutation status (19del or 21 L858R);

Calculate the time from the start date to the end of follow-up treatment. The results are shown in months, to one decimal place. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

Calculate the interval of operation to the follow-up treatment with EGFR-TKI, which is classified into single-drug therapy and combined therapy. The results are shown in months, to one decimal place. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

The patients with chemotherapy of follow-up treatment were mainly calculated, divided into chemotherapy and targeted combination chemotherapy. The total number of chemotherapy cycles, the number of missing cases, the mean, standard deviation, the median, the 25th and 75th percentiles, the minimum and the maximum were statistically described

The First Affiliated Hospital of Guangzhou Medical University

Clinical Professor

Surgeries or surgeries plus adjuvant therapies

Lunxun Liu, PhD

The study was designed to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors

The trial is a multi-centre real-world non-interventional observational study to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors via a retrospectively review method on the study data on patient demographic/tumor biological characteristics and clinical treatments.

A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Clinical Characteristics of the Chinese Patients With Lung Malignant Tumors Who Received Surgeries or Surgeries Plus Adjuvant Therapies

Differences in perioperative overall survivals and overall survivals of the patients who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery

Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by tumor clinical/pathological staging

Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by location of tumors and tumor sizes

Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by duration and modes of surgeries

Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by type of insurances

Overall survival in the patients with tumor size =\< 2cm who received surgeries

Impact factors of patient survivals in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies

Overall survival in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies

Impact factors of patient survivals in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies

Overall survival in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies

Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies as measured by:

* Age
* Gender
* Payment types
* Insurance types
* Smoking history
* Complications and symptoms of complications
* Respiratory functions
* Type of diagnoses

Demographic characteristics of the patients with lung malignant tumors who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery as measured by:

* Age
* Gender
* Payment types
* Insurance types
* Smoking history
* Complications and symptoms of complications
* Respiratory functions
* Type of diagnoses

West China Hospital

Patients who received radical resection of lung cancer + adjuvant chemotherapies

Patients who received perioperative chemotherapies

Surgeries plus adjuvant chemotherapies or perioperative chemotherapies

The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cancer

The trial is a multi-centre real-world non-interventional observational study. The Chinese patients with N2 non-small cell lung cancer enrolled from 2014 to 2017 who received radical resections of lung cancer and adjuvant chemotherapies will be included in the study and the study data on patient demographic/tumor biological characteristics and clinical treatment will be collected to evaluate compare effectiveness of radical resection of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies after surgeries.

A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer

A Multi-centre Real-world Non-interventional Observational Study to Compare Prognoses of the Chinese Patients With N2 Non-small Cell Lung Cancer Who Received Adjuvant Chemotherapies and Perioperative Chemotherapies After Surgeries

Overall survivals in the subgroups categorized by T staging

Disease-free survivals in the subgroups categorized by T staging

Impact factors of overall survival as measured by age

Impact factors of overall survival as measured by gender

Impact factors of overall survival as measured by BMI

Impact factors of overall survival as measured by tumor size

Impact factors of overall survival as measured by tumor location

Impact factors of overall survival as measured by T staging

Impact factors of overall survival as measured by surgeries plus adjuvant chemotherapies and surgeries plus perioperative chemotherapies

Impact factors of death rate within 30/90 days after surgeries as measured by patient demographic characteristics

Impact factors of death rate within 30/90 days after surgeries as measured by tumor biological characteristics

Impact factors of death rate within 30/90 days after surgeries as measured by various modes of surgeries

Tang-Du Hospital

Symptoms and General Pathology

Neoplasm Metastasis

Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries

Lin Xu

The real-world observational study was designed to explore the odd factors of lymph metastases in the patients with T1 non-small cell lung cancer, the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.

The trial is a multi-centre, real-world non-interventional observational study. In the study, the patients with T1 non-small cell lung cancer enrolled in clinics from 2015 to 2017 were included via a retrospectively review method and the study data on patient demographic/tumor biological characteristics, and clinical treatments were collected to explore the clinical odd factors of lymph metastases, evaluate the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.

An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer

A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of the Chinese Patients With T1 Non-small Cell Lung Cancer Complicated With Lymph Metastases

Percentages of N2 patients with lymph nodes in N2 population

Percentage of patients with lymph metastases categorised by tumor baseline characteristics

Number of lymph nodes in N2 patients categorised by tumor baseline characteristics

Percentage of patients with N2 skip metastases categorised by tumor baseline characteristics

Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics

Percentages of N0/N1/N2/N3 patients in the target population

Jiangsu Cancer Institute & Hospital

Associate professor

Digestive System Diseases

Rare Diseases

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries

Haiying Yang

Chunya Chen

Deruo Liu, PhD

Yang Liu, PhD

Yin Li, PhD

Lin Xu, PhD

Xiaofei Li, PhD

Heng Zhao, PhD

Lunxu Liu, PhD

Xun Zhang, PhD

Jian Hu, PhD

Yin Li

The real-world observational study was designed to explore lymph metastases and prognoses of the Chinese patients with thoracic T1-T3 esophageal cancer

This trial is a real-world non-interventional observational study. The Chinese patients with thoracic T1-T3 esophageal cancer enrolled from Jan.1999 to Jun.2017 were included and the study data on pathologically diagnosed patient demographic/tumor biological characteristics were collected to evaluate the relevance of lymph metastases and prognoses of the subjects.

An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer

A Real-world Observational Study to Evaluate Lymph Metastases and Prognoses of the Chinese Patients With Thoracic T1-T3 Esophageal Cancer

Effects on lymph metastases on overall survival in the patients with thoracic esophageal cancer

Effects of the numbers of lymph nodes on overall survival in the patients with thoracic esophageal cancer who received lymphadenectomy

Effects of surgeries on the percentages of the thoracic T1-T3 patients with esophageal cancer who received lymphadenectomy

Effects of surgeries on the extents of the thoracic T1-T3 patients with esophageal cancer who received surgeries

Numbers of lymph nodes and percentages of patients with surgeries in the patients with thoracic T1-T3 esophageal cancer

Henan Cancer Hospital

Haiying Yang, PhD

Xiangning Fu, PhD

Xiaofei Fu, PhD

An observational study to explore prognoses and clinical treatments of the patients with non-small cell lung cancer complicated with oligometastases

A multi-centre real-world non-interventional observational study to explore prognoses and clinical treatments of the patients with non-small lung cancer complicated with oligometastases

A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases

A Multi-centre Real-world Non-interventional Observational Study to Explore Prognoses of the Patients With Non-small Cell Lung Cancer Complicated With Oligometastases

Spots Global Cancer Trial Database for surgeries

Every month we try and update this database with for surgeries cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients	NCT03429673	Non-small Cell ...	Surgeries	65 Years -	China-Japan Friendship Hospital
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China	NCT04830826	NSCLC, Stage I NSCLC, Stage II NSCLC, Stage II...	Surgeries	-	The First Affiliated Hospital of Guangzhou Medical University
A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies	NCT03421093	Lung Cancer	Surgeries	18 Years -	West China Hospital
A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer	NCT03451526	Non-small Cell ...	Surgeries	18 Years -	Tang-Du Hospital
An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer	NCT03413956	Non Small Cell ...	Surgeries	-	Jiangsu Cancer Institute & Hospital
An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer	NCT03415815	Esophageal Canc...	Surgeries	18 Years -	Henan Cancer Hospital
A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases	NCT03427541	Non Small Cell ...	Surgeries	-	Tang-Du Hospital
A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases	NCT03427541	Non Small Cell ...	Surgeries	-	Tang-Du Hospital

Spots Global Cancer Trial Database for surgeries

Every month we try and update this database with for surgeries cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for surgeries cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.